AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
20 Nov 2024 04:00 PM
RNS
Director/PDMR Shareholding
18 Nov 2024 07:00 AM
RNS
Tagrisso recommended for EU approval - LAURA
15 Nov 2024 02:00 PM
RNS
Director/PDMR Shareholding
15 Nov 2024 10:00 AM
RNS
Director/PDMR Shareholding
13 Nov 2024 04:00 PM
RNS
Director/PDMR Shareholding
12 Nov 2024 07:10 AM
RNS
AstraZeneca invests $3.5 billion in US
12 Nov 2024 07:05 AM
RNS
KOMET Phase III trial met primary endpoint
12 Nov 2024 07:00 AM
RNS
9M and Q3 2024 Results
12 Nov 2024 07:00 AM
RNS
Dato-DXd new BLA submitted, NSQ BLA withdrawn
08 Nov 2024 07:00 AM
RNS
Tezspire nasal polyps trial met primary endpoints
05 Nov 2024 04:49 PM
RNS
AZN share price movement
01 Nov 2024 03:00 PM
RNS
Total Voting Rights
30 Oct 2024 01:00 PM
RNS
AZN China President under investigation
21 Oct 2024 07:00 AM
RNS
Wainzua recommended for approval in the EU
07 Oct 2024 09:30 AM
RNS
AstraZeneca licenses lipid lowering Lp(a) asset
01 Oct 2024 03:00 PM
RNS
Total Voting Rights
26 Sep 2024 07:00 AM
RNS
Tagrisso US approval in unresectable lung cancer
23 Sep 2024 07:05 AM
RNS
Fasenra recommended for EU approval in EGPA
23 Sep 2024 07:00 AM
RNS
Final OS results reported for TROPION-Breast01
20 Sep 2024 06:00 PM
RNS
FluMist approved for self-administration in US
18 Sep 2024 07:00 AM
RNS
Fasenra EGPA US FDA approval
13 Sep 2024 03:15 PM
RNS
Director/PDMR Shareholding
02 Sep 2024 03:00 PM
RNS
Total Voting Rights
16 Aug 2024 07:00 AM
RNS
Imfinzi approved in US for resectable lung cancer
01 Aug 2024 03:00 PM
RNS
Total Voting Rights
30 Jul 2024 07:00 AM
RNS
AstraZeneca prices a €1.4bn bond offering
29 Jul 2024 08:41 AM
RNS
Stabilisation Notice - ASTRAZENECA
29 Jul 2024 07:00 AM
RNS
Calquence fixed-duration combo improved 1L CLL PFS
26 Jul 2024 07:00 AM
RNS
ODAC reviewed Imfinzi in resectable lung cancer
25 Jul 2024 07:00 AM
RNS
Half-year Report
15 Jul 2024 07:00 AM
RNS
Acquisition of Amolyt Pharma completed
01 Jul 2024 03:00 PM
RNS
Total Voting Rights
01 Jul 2024 07:00 AM
RNS
Lynparza & Imfinzi positive CHMP in endometrial
25 Jun 2024 07:05 AM
RNS
Update on Imfinzi ADJUVANT BR.31 trial
25 Jun 2024 07:00 AM
RNS
Imfinzi improved EFS and OS in bladder cancer
18 Jun 2024 07:00 AM
RNS
Update on CAPItello-290 Phase III trial
17 Jun 2024 07:00 AM
RNS
Imfinzi approved in the US for endometrial cancer
12 Jun 2024 03:00 PM
RNS
Director/PDMR Shareholding
05 Jun 2024 07:00 AM
RNS
Acquisition of Fusion completed
03 Jun 2024 03:05 PM
RNS
Block listing Interim Review
03 Jun 2024 03:00 PM
RNS
Total Voting Rights
03 Jun 2024 07:00 AM
RNS
Tagrisso plus chemo recommended for approval in EU
28 May 2024 07:00 AM
RNS
Dato-DXd improved OS in nonsquamous lung cancer
21 May 2024 07:00 AM
RNS
AstraZeneca to deliver $80bn revenue by 2030
20 May 2024 07:00 AM
RNS
AstraZeneca to manufacture ADCs in Singapore
16 May 2024 07:00 AM
RNS
SUPERNOVA Trial Met COVID-19 prevention endpoint
15 May 2024 03:00 PM
RNS
Director/PDMR Shareholding
07 May 2024 07:00 AM
RNS
AstraZeneca completes Cellectis equity investment
02 May 2024 07:00 AM
RNS
Calquence combination improved PFS in 1L MCL
01 May 2024 03:00 PM
RNS
Total Voting Rights

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings